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Chondrosarcomas are the second largest group of malignant 
bone tumors following osteosarcoma, and they arise from 
various sites including extremity, trunk, spine, and head 
[1]. Because of their resistance to chemotherapy and radio-
therapy, surgical resection is the only treatment for chon-
drosarcomas; however, they often recur after incomplete 
resection or metastasis [2]. Therefore, novel strategies are 
crucial to overcome the malignancy of chondrosarcomas.
Peroxisome proliferator- activated receptor gamma 
(PPARγ) is a ligand- activated transcription factor that 
belongs to the nuclear hormone receptor superfamily [3]. 
PPARγ plays a central role in the differentiation of adi-
pocytes and is reported to be expressed in various malig-
nant tumors [4]. Anti- tumorigenic effects through ligand 
activation of PPARγ have been demonstrated in certain 
malignancies [5, 6]. Furthermore, in chondrosarcoma, 
PPARγ has been considered as a possible therapeutic target 
[7]. We have recently reported a case of giant cell tumor 
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Abstract
Surgical resection is the only treatment for chondrosarcomas, because of their 
resistance to chemotherapy and radiotherapy; therefore, additional strategies are 
crucial to treat chondrosarcomas. Peroxisome proliferator- activated receptor 
gamma (PPARγ) is a ligand- activated transcription factor, which has been re-
ported as a possible therapeutic target in certain malignancies including chon-
drosarcomas. In this study, we demonstrated that a nonsteroidal anti- 
inflammatory drug, zaltoprofen, could induce PPARγ activation and elicit 
anti- tumor effects in chondrosarcoma cells. Zaltoprofen was found to induce 
expressions of PPARγ mRNA and protein in human chondrosarcoma SW1353 
and OUMS27 cells, and induce PPARγ- responsible promoter reporter activities. 
Inhibitory effects of zaltoprofen were observed on cell viability, proliferation, 
migration, and invasion, and the activity of matrix metalloproteinase- 2 (MMP2); 
these effects were dependent on PPARγ activation and evidenced by silencing 
PPARγ. Moreover, we showed a case of a patient with cervical chondrosarcoma 
(grade 2), who was treated with zaltoprofen and has been free from disease 
progression for more than 2 years. Histopathological findings revealed enhanced 
expression of PPARγ and reduced expression of MMP2 after administration of 
zaltoprofen. These findings demonstrate that zaltoprofen could be a promising 
drug against the malignant phenotypes in chondrosarcomas via activation of 
PPARγ and inhibition of MMP2 activity.
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of bone, in which complete necrosis and high expression 
of PPARγ appeared in the resected specimen after zalto-
profen administration [8]. Zaltoprofen is a propionic- acid 
derivative of nonsteroidal anti- inflammatory drugs 
(NSAIDs) [8]. Previous studies have shown that several 
NSAIDs could serve as exogenous ligands for PPARγ 
[9–11]. We consider the possibility of anti- tumorigenic 
effects by zaltoprofen via the activation of PPARγ in 
musculoskeletal neoplasms.
Matrix metalloproteinase- 2 (MMP2) is a member of 
the MMP family and can degrade matrix collagen and 
basement membrane, which plays a critical role in tumor 
invasion and metastasis [12, 13]. Overexpression of MMP2 
has been detected in various types of cancer, including 
chondrosarcomas [14]. Therefore, the inhibition of MMP2 
is a potent strategy to suppress tumor progression in 
chondrosarcoma [14, 15]. Recent studies report that the 
activation of PPARγ inhibited MMP2 production and 
tumor cell invasion in several types of cancer, indicating 
that downregulation of MMP2 by PPARγ could represent 
an anti- tumorigenic procedure [16, 17].
The purpose of this study was to assess the anti- tumor 
effects of zaltoprofen via regulation of MMP2 and PPARγ 
activity, and examine whether zaltoprofen could be a novel 
therapeutic agent in human chondrosarcoma.
Material and Methods
Cells and reagents
Human chondrosarcoma cell lines, OUMS27, and 
SW1353 were purchased from Japanese Collection of 
Research Bioresources Cell Bank (JCRB Cell Bank, Tokyo, 
Japan) and American Type Culture Collection (ATCC, 
Manassas, VA), respectively. They were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Wako 
Pure Chemical Industries, Ltd., Osaka, Japan) supple-
mented with 10% fetal bovine serum (FBS), penicillin 
(100 U/mL) and streptomycin (100 μg/mL) at 37°C. 
Zaltoprofen and ARP100, a selective MMP2 inhibitor, 
were purchased from Santa Cruz (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) and dissolved in 
dimethyl sulfoxide (DMSO).
Western blot analysis
OUMS27 and SW1353 cells treated with various con-
centrations of zaltoprofen for 24 h were lysed by RIPA 
buffer (150 mmol/L NaCl, 1% sodium deoxycholate, 
1% Triton X- 100, 0.1% SDS, 10 mmol/L Tris, pH 7.2, 
100 μmol/L sodium orthovanadate, and 50 mmol/L 
sodium fluoride) containing protease cocktail inhibitors 
(Sigma- Aldrich Co., Munich, Germany). The cell lysates 
(100 μg) were boiled in SDS sample buffer, resolved 
by SDS- PAGE (12.5%), run on an e- PAGEL (ATTO 
Co., Tokyo, Japan), and then transferred onto PVDF 
membrane (Merck Millipore, Darmstadt, Germany). 
The membranes were blocked with Odyssey Blocking 
Buffer PBS (LI- COR Inc., Lincoln, NE) for 1 h and 
then reacted with a mouse monoclonal anti- PPARγ 
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) at 4°C for 24 h. After washing with PBS with 
Tween- 20, the membranes were reacted with IRDye 
680 anti- mouse IgG (LI- COR Inc., Lincoln, NE) for 
30 min, and immunoreacted bands were visualized 
using the Odyssey Infrared Imaging system (LI- COR 
Inc., Lincoln, NE). The glyceraldehyde- 3- phosphate 
dehydrogenase (GAPDH) protein was used as a house-
keeping protein and detected with a monoclonal anti- 
GAPDH antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA).
Quantitative real- time reverse transcription- 
polymerase chain reaction (qRT- PCR)
After treatment with zaltoprofen for 24 h, total RNA 
extracted from OUMS27 and SW1353 cells using Ambion 
TRIzol reagent (Invitrogen, Carlsbad, CA) was quantified 
using a NanoDrop Lite spectrophotometer (Thermo Fisher 
Scientific Inc., Waltham, MA). The RNA sample (100 ng) 
was reverse- transcribed into cDNA on a T100 Thermal 
Cycler (Bio- Rad Laboratories, Inc., Hercules, CA) using 
AffinityScript cDNA Synthesis Kit (Agilent Technologies 
Inc., Santa Clara, CA) in accordance with the manufac-
turer’s instructions. The qRT- PCR was performed with 
10 ng cDNA per well on a StepOne™ Real- time PCR 
System (Applied Biosystems, Waltham, MA) using the 
QuantiTect SYBR Green PCR Kits (Qiagen, Hilden, 
Germany). GAPDH was used as an internal control. Primers 
used for qRT- PCR were as follows: primer for PPARγ 
was purchased by Qiagen (QuantiTect Primer Assay, 
PPARG). GAPDH forward, 5′- TGCACCA- CCAACTGC 
TTAGC- 3′; reverse, 5′- GGCATGGACTGTGGTCATGA 
G- 3′.
PPARγ reporter assay
PPARγ activity was assessed using a luciferase reporter 
gene assay kit (INDIGO Biosciences, Inc., State College, 
PA), according to the manufacturer’s instructions [18]. 
Briefly, reporter cells were dispensed into wells and then 
immediately treated with zaltoprofen. Following 24 h 
incubation, treatment media were discarded and luciferase 
detection reagent was added. The intensity of light emis-
sion from each sample well was quantified using a plate- 
reading luminometer (TriStar LB 941 Multimode 
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Microplate Reader, Berthold Technologies, Bad Wildbad, 
Germany).
PPARγ knockdown
SureSilencing short hairpin RNA (shRNA) plasmid for 
human PPARγ (Qiagen, Hilden, Germany) was used to 
knockdown PPARγ gene. PPARγ- specific shRNA (shPPAR) 
or nontarget control shRNA (shNTC) plasmid were trans-
fected in OUMS27 and SW1353 cells using Attractene 
transfection reagent (Qiagen, Hilden, Germany) according 
to the manufacturer’s protocol [19].Transfected cells were 
selected by resistance to 600 μg/mL neomycin (G418 solu-
tion, Roche Diagnostics, Indianapolis, IN) and the knock-
down efficiency was confirmed by qRT- PCR. Insert sequence 
of PPARγ- specific shRNA is CCACGAGATCATTACACA 
AT, and nontarget control shRNA is GGAATCTCATTCGAT 
GCATAC. Finally, we established PPARγ knockdown cell 
lines (SW- 1353shPPAR and OUMS- 27shPPAR) and nontarget 
control cell lines (SW- 1353shNTC and OUMS- 27shNTC).
Cell proliferation assay
The cell proliferation assay was performed using a Cell 
Counting Kit- 8 (Dojindo Laboratory, Mashiki- machi, 
Japan). Briefly, 5 × 103 cells/well were seeded in 96- well 
plates. After 24 h incubation at 37°C, indicated concen-
trations of zaltoprofen were added to the medium, and 
after further 72 h of incubation, the medium was removed 
and a Cell Counting Kit- 8 reagent was added to the 
plates. After a final incubation at 37°C for 2 h, the 
absorbance was measured at 450 nm by a microplate 
reader (iMark Microplate Absorbance Reader, Bio- Rad 
Laboratories, Inc., Hercules, CA). In addition, 
5- ethynyl- 2′- deoxyuridine (EdU) proliferation assay was 
carried out using Click- iT® EdU Alexa Fluor® 555 Imaging 
Kit (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s protocol [20]. Briefly, OUMS27shPPAR, 
OUMS27shNTC, SW1353shPPAR, and SW1353shNTC were 
seeded on slide chambers and incubated overnight. After 
treatment with zaltoprofen (400 μmol/L) or DMSO for 
24 h, cells were treated with EdU (10 mmol/L) for 1 h. 
Then, they were fixed with 4% paraformaldehyde (Wako 
Pure Chemical Industries, Ltd., Osaka, Japan), washed 
with 3% bovine serum albumin in PBS, and permeabilized 
with 0.5% Triton X- 100. Cells were then incubated with 
the Click- iT reaction cocktail, followed by Hoechst 33342 
(NucBlue Live ReadyProbes Reagent, Invitrogen, Carlsbad, 
CA), and were observed using fluorescence microscope 
(BZ- 9000, Keyence Co., Osaka, Japan). The number of 
EdU- positive cells and Hoechst 33342- positive cells was 
counted using Image J software according to the manu-
facturer’s instructions [21].
Cell migration assay
Cell migration was evaluated by a monolayer denudation 
assay as described previously [22]. Briefly, OUMS27shPPAR, 
OUMS27shNTC, SW1353shPPAR, and SW1353shNTC were 
seeded at a density of 1 × 106 cells/well and grown to 
confluence in a 6- well plate. Cells were then wounded 
by denuding a strip of the monolayer approximately 1 mm 
in width with a 200 μL pipette tip. After washing cells 
with serum- free DMEM, DMSO (0.1%), zaltoprofen (200 
or 400 μmol/L), a selective MMP2 inhibitor, and ARP100 
(25 μmol/L) were added to each well, and then cells were 
incubated for 30 h. The rate of wound closure was assessed 
in six separate fields using Image J software [23].
Cell invasion assay
The invasive potential of OUMS27shPPAR, OUMS27shNTC, 
SW1353shPPAR, and SW1353shNTC was assessed using 
Matrigel invasion chambers (24- well, 8 μm pore size) (BD 
Biosciences, San Diego, CA) [24]. Cells were plated into 
the upper chamber at an initial density of 4 × 104 cell/
ml in 0.5 mL serum- free DMEM, and 0.5 mL of DMEM 
supplemented with 10% FBS and fibronectin 500 μg/mL 
was added to the bottom chambers as chemoattractant. 
After 24 h incubation in the presence of DMSO (0.1%), 
zaltoprofen (200 or 400 μmol/L) and ARP100 (25 μmol/L) 
into both the upper and bottom chambers, the noninvasive 
cells that remained at the top chambers were removed 
by scraping using a cotton swab, and the invasive cells 
at the bottom of the membranes were fixed with methanol. 
Cells were then washed twice with PBS and stained with 
1% crystal violet for 30 min at RT. The invasive cells 
were counted in six separate fields using an optical micro-
scope at 20× magnification [24].
Gelatin zymography analysis
The expression of activated MMPs in conditioned medium 
was assayed by gelatin zymography [25]. The cells 
(OUMS27shPPAR, OUMS27shNTC, SW1353shPPAR, and 
SW1353shNTC) were seeded at a density of 1 × 106 cells/
well and grown to 70–80% confluency in a 6- well plate. 
Then the cells were cultured in serum- free DMEM con-
taining DMSO (0.1%) or zaltoprofen (200 or 400 μmol/L) 
for 24 h. Afterward, the supernatants were collected and 
mixed with 5× SDS sample buffer without reducing agent 
or heating. The samples were loaded onto a Gelatin- 
zymography Precast GEL (Cosmo Bio Co., Ltd., Tokyo, 
Japan) and subjected to electrophoresis. Following elec-
trophoresis, the gel was washed twice with 2.5% Triton 
X- 100, 10 mmol/L Tris- HCl (pH 8.0) for 30 min to 
remove SDS, and then incubated in 1 μmol/L ZnCl2, 
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10 mmol/L CaCl2, 0.2 mol/L NaCl, and 50 mmol/L Tris- 
HCl (pH 8.0) for 28 h at 37°C. Enzyme activity was 
visualized as negative staining with Coomassie Brilliant 
Blue R250 and gel was washed with destaining solution 
until clear bands were visible.
A clinical case of chondrosarcoma with 
zaltoprofen administration
A 34- year- old man presented with grade 1 chondrosar-
coma of cervical spine underwent tumor excision by 
his previous doctor. After 1 year from initial surgery, 
recurrent tumor was detected and excised by the same 
doctor, and the pathological diagnosis of the resected 
section was grade 2 chondrosarcoma. Although, adjuvant 
radiotherapy was conducted, the tumor had gradually 
enlarged. After 3 years from second surgery, he was 
referred to our hospital for severe pain and numbness 
of the left upper arm. There was bone destruction of 
the preserved vertebral arch and the tumor invaded the 
spinal canal, excluding the dura of cervical spine from 
anterolateral side of C5- 6. We performed radiotherapy 
and tumor excision of the posterior side of C2- 4. 
However, the tumor of C5- 6 was unresectable; hence, 
240 mg/day of zaltoprofen was administered to the 
patient against his persistent pain and numbness on 
the neck and the left upper arm. For approximately 
2 years since zaltoprofen administration, the tumor 
remained within mild growth for grade 2 chondrosar-
coma; however, instability and anteflexion of the cervical 
spine proceeded. Therefore, the patient underwent tumor 
excision and posterior fixation of the cervical spine. At 
the final follow- up, the patient was alive with disease 
without distant metastasis for more than 7 years after 
the initial diagnosis and 4 years after the administration 
of zaltoprofen (Fig. 5). The resection paraffin sections 
of two different treatment periods, the second surgery 
(preadministration specimen, Pre) and final surgery 
(postadministration specimen, Post), were used for 
hematoxylin- Eosin (HE) staining and PPARγ and MMP2 
immunofluorescent staining with anti- PPARγ antibody 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and 
anti- MMP2 antibody (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA), respectively, in combination with IRDye 
680 anti- mouse IgG (LI- COR Inc., Lincoln, NE) as a 
secondary antibody. Nuclear staining was performed with 
4′, 6- diamidino- 2- phenylindole (DAPI).
Consent for use of human specimens
Declaration of Helsinki protocols were followed and the 
patient gave their written, informed consent, which was 
approved by the Ethics Committee of Kanazawa University.
Statistical analysis
Each experiment was repeated independently at least three 
times. All data are presented as mean ± SEM. Student’s 
t- test and ANOVA using the Tukey- Kramer post hoc test 
were used when mean differences were identified between 
the groups. All P- values were two- sided and P- values of 
0.05 or less were considered statistically significant. All 
statistical analyses were performed with EZR (Saitama 
Medical Center, Jichi Medical University, Saitama, Japan) 
[26], which is a graphical user interface for R (The R 
Foundation for Statistical Computing, Vienna, Austria).
Results
Effects of zaltoprofen on the induction and 
activation of PPARγ in chondrosarcoma cells
qRT- PCR demonstrated a significant upregulation of PPARγ 
mRNA in OUMS27 and SW1353 cells after 24 h- treatment 
with 400 μmol/L zaltoprofen (Fig. 1A). Moreover, zalto-
profen treatment dose- dependently increased expression 
levels of PPARγ protein in both cell lines as observed by 
western blotting (Fig. 1B), indicating that zaltoprofen induces 
PPARγ expression in chondrosarcoma cells. We next inves-
tigated the activity of PPARγ using a luciferase reporter 
assay system. The zaltoprofen treatment could significantly 
and dose- dependently upregulate PPARγ- responsible pro-
moter activities, and the EC50 (effective concentration) was 
found to be 47.3 μmol/L (Fig. 1C); this suggests a strong 
induction of PPARγ activity, with a relatively mild upregu-
lation of PPARγ expression by zaltoprofen.
Inhibitory effects of zaltoprofen on the 
viability and proliferation of 
chondrosarcoma cells
We next investigated whether zaltoprofen could reduce the 
viability of OUMS27 and SW1353 chondrosarcoma cell lines 
in vitro. When cells were treated with various concentra-
tions (0–400 μmol/L) of zaltoprofen for 72 h, cell viability 
of OUMS27 and SW1353 cells was significantly and dose- 
dependently lowered by zaltoprofen treatment (Fig. 2A). In 
addition, cell proliferation assay was performed to evaluate 
EdU incorporation into the nucleus. The number of EdU- 
incorporated cells per Hoechst 33342- positive nuclei ratio 
was calculated and the involvement of PPARγ in the cell 
proliferation was analyzed with or without downregulation 
of PPARγ by a specific shRNA knockdown system (Fig. 2B). 
As a result, the EdU- positive cell ratio was significantly and 
dose- dependently decreased by the treatment of zaltoprofen 
in both OUMS27 and SW1353 cells, when compared to 
controls (Fig. 2C and D). Moreover, the downregulation 
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of the EdU- positive cell ratio by zaltoprofen was significantly 
inhibited by PPARγ silencing in chondrosarcoma cells, 
OUMS27shPPAR and SW1353shPPAR cells (Fig. 2C and D). 
These data suggest that inhibitory effects on cell viability 
and proliferation by zaltoprofen were via PPARγ.
Inhibitory effects of zaltoprofen on cell 
migration and invasion in chondrosarcoma 
cells
To examine whether zaltoprofen contributes to tumor malig-
nancy in terms of metastatic potentials, we performed in 
Figure 1. (A) Effects of zaltoprofen on PPARγ mRNA expression in OUMS27 and SW1353 cells by qRT- PCR. Values represented as the mean ± SEM. 
Asterisks denote a statistically significant difference (*P < 0.05 and **P < 0.01) between cells with and without treatment of zaltoprofen (400 μmol/L). 
(B) Effects of zaltoprofen on PPARγ protein expression in OUMS27 and SW1353 cells by western blotting. GAPDH was used as an internal control. (C) 
PPARγ activity was determined by luciferase reporter gene assay. Reporter cells were treated with zaltoprofen (0–200 μmol/L) for 24 h, followed by 
measurement of luciferase activities.
Figure 2. (A) Effects of zaltoprofen on the viability of OUMS27 and SW1353 cells. The cells were treated with or without zaltoprofen for 72 h, 
followed by WST assay. Asterisks denote a statistically significant difference (*P < 0.05) between cells with and without treatment of zaltoprofen (200 
or 400 μmol/L). (B) Representative photos of 5- ethynyl- 2′- deoxyuridine (EdU) proliferation assay in PPARγ knockdown cell lines, OUMS27shPPAR and 
SW1353shPPAR, and the control cell lines, OUMS27shNTC and SW1353shNTC with or without the treatment of zaltoprofen for 24 h. Scale bar = 100 μm. 
(C, D) The EdU- positive cell ratio [EdU- positive nuclei (red)/Hoechst 33342- positive nuclei (blue)] in OUMS27 (C) and SW1353 cells (D). Values 
represented as the mean ± SEM. Asterisks denote a statistically significant difference (*P < 0.05 and **P < 0.01).
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vitro cell migration assays and cell invasion assay using 
transwell inserts coated with a reconstituted basement mem-
brane barrier (Matrigel). First, in vitro cell migration assays 
were performed and fielded wound area (%) was calculated 
(Fig. 3). Zaltoprofen at a concentration of 400 μmol/L and 
200 μmol/L significantly and partially inhibited cell migra-
tion of both OUMS27 and SW1353 cells, respectively (Fig. 3). 
Positive control ARP100 (25 μmol/L), a selective MMP2 
inhibitor, also showed a significant inhibitory effect on cell 
migration (Fig. 3). PPARγ silencing in chondrosarcoma cells, 
OUMS27shPPAR and SW1353shPPAR, exhibited a significant 
inhibition of cell migration even in the nontreated control 
and following cancelation of the inhibitory effect by zalto-
profen, as well as ARP100 (Fig. 3). Second, we employed 
a Matrigel cell invasion assay with zaltoprofen and ARP100. 
Zaltoprofen significantly and dose- dependently inhibited cell 
invasion of SW1353 cells (Fig. 4A and B). ARP100 signifi-
cantly inhibited cell invasion of SW1353 cells at a concen-
tration of 25 μmol/L (Fig. 4A and B). In the absence of 
zaltoprofen or ARP100, PPARγ silencing SW1353shPPAR cells 
showed a significant increase in cell invasion when compared 
to control SW1353shNTC cells, suggesting a PPARγ- dependent 
inhibition of cell invasion, which was on the contrary to 
obtained data on cell migration (Fig. 4A and B). However, 
zaltoprofen treatment significantly blocked invasion of 
SW1353shPPAR cells, speculating the involvement of a PPARγ- 
independent effect of zaltoprofen (Fig. 4A and B).
Inhibitory effects of zaltoprofen on MMP2 
expression in chondrosarcoma cells
The data on the selective MMP2 inhibitor, ARP100, led 
us to investigate the relationship between MMP2 and 
zaltoprofen. Gelatin zymography showed downregulation 
of MMP2 enzyme activities by zaltoprofen at 400 μmol/L 
in OUMS27shNTC and SW1353shNTC cells (Fig. 4C). 
However, in OUMS27shPPAR and SW1353shPPAR cells, the 
downregulation of MMP2 activities by zaltoprofen was 
inhibited by PPARγ silencing (Fig. 4C), thus, suggesting 
that a zaltoprofen- induced PPARγ activation could reduce 
MMP2 activities in chondrosarcoma cells.
A clinical case of chondrosarcoma treated 
with zaltoprofen
We experienced a case of chondrosarcoma with uninten-
tional zaltoprofen treatment. (Fig. 5). A specimen was 
obtained from the patient with grade 2 chondrosarcoma 
before administration of zaltoprofen (preadministration, 
Pre), and the microscopic data showed several nuclei with 
irregular shape and mitoses (Fig. 6A). In contrast, in the 
postadministration (Post) specimens, less nuclei with 
irregular shape or mitoses were found, and sporadic myxoid 
degeneration and necrotic portions were observed 
(Fig. 6A). Immunofluorescent staining of PPARγ and 
Figure 3. (A) Cell migration assay was carried out using PPARγ knockdown cell lines, OUMS27shPPAR and SW1353shPPAR, and the control cell lines, 
OUMS27shNTC and SW1353shNTC with or without the treatment of zaltoprofen. A selective inhibitor of MMP2, ARP100, was used at 25 μmol/L. Scale 
bar = 100 μm. (B, C) The fielded wound area (%) was calculated in OUMS27 (B) and SW1353 cells (C). Values represented as the mean ± SEM. 
Asterisks denote a statistically significant difference (*P < 0.05 and **P < 0.01).
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MMP2 demonstrated that the expression of PPARγ was 
enhanced, but that of MMP2 was reduced, after the 
administration of zaltoprofen (Fig. 6B and C).
Discussion
In the present study, we found that zaltoprofen could 
dose- dependently upregulate PPARγ activities and signifi-
cantly, but mildly, induce PPARγ expression in human 
chondrosarcoma OUMS27 and SW1353 cells (Fig. 1). 
Zaltoprofen inhibited cell viability and proliferation as 
well as cell migration in a PPARγ- dependent manner in 
OUMS27 and SW1353 cells (Figs. 2 and 3). Although 
cell invasion was significantly reduced by zaltoprofen treat-
ment, PPARγ- knockdown could not cancel the effects of 
zaltoprofen (Fig. 4A and B), suggesting two possibilities 
including an inhibitory action of PPARγ against cell inva-
sion and a PPARγ- independent effect of zaltoprofen on 
cell invasion. In addition, the downregulation of MMP2 
activity by zaltoprofen was dependent on PPARγ expres-
sion (Fig. 4C).
It has been reported that PPARγ is closely associated 
with malignant tumors [4]. Recent studies suggest that 
PPARγ ligands can be useful anti- tumor agents in cancer 
Figure 4. (A) Cell invasion assay was carried out using a PPARγ knockdown cell line SW1353shPPAR and the control cell line SW1353shNTC with or 
without the treatment of zaltoprofen. A selective inhibitor of MMP2, ARP100, was used at 25 μmol/L. Scale bar = 100 μm. (B) Relative invaded cell 
number was calculated. Values represented as the mean ± SEM. Asterisks denote a statistically significant difference (**P < 0.01). (C) Gelatin 
zymography. Effects of zaltoprofen (400 μmol/L) on MMP2 activities in PPARγ knockdown cell lines, OUMS27shPPAR and SW1353shPPAR, and the 
control cell lines, OUMS27shNTC and SW1353shNTC.
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cells [5, 6]. Endogenous and exogenous ligands for PPARγ 
include fatty acids, eicosanoids, fibrates, thiazolidine deriva-
tives, angiotensin receptor blockers, and NSAIDs [3, 8, 
27]. Among them, NSAIDs such as indomethacin, 
diclofenac, oxaprozin, and zaltoprofen have been reported 
as potent ligands for PPARγ [8] and anti- tumor agents 
against colorectal and lung cancers [28, 29]. This is the 
first report of anti- cancer effects of zaltoprofen against 
malignant musculoskeletal tumors. Activation of PPARγ 
is reported to drive the positive feedback loop upregulat-
ing the PPARG gene per se via direct binding of PPARγ/
RXRα heterodimers to the PPARG promoter [30]. However, 
the involvement of other transcriptional activation factors 
for PPARG, including CEBPs and KLFs, is still unclear 
in the PPARγ upregulation by zaltoprofen. It is also 
interesting to examine whether zaltoprofen can selectively 
activate not only PPARγ, but also PPARα or PPARδ, in 
terms of the anti- tumor effects of zaltoprofen. Further 
studies are required to elucidate the overall mechanisms 
of action of zaltoprofen on the anti- cancer activity.
MMP2, the 72 kDa gelatinase A/Type IV collagenase, 
plays an important role in the tumorigenic processes, such 
as tumor invasion and metastasis [12, 31]. Therefore, the 
inhibition of MMP2 activation has been suggested to be 
a potent strategy for the prevention of cancer cell metastasis 
[31]. To date, several MMP2 inhibitors have been developed 
for clinical use. In chondrosarcomas, the expression of 
MMP2 has been confirmed and demonstrated a significant 
correlation with the tumor histological grade linking to 
the prognosis [14]. Therefore, MMP2 could be a possible 
Figure 5. (A, B) Sagittal, MRI T2 weighted image of cervical spine at first visit on the initial hospital before (A) and after (B) the surgery. The tumor 
(arrow) was resected (1st operation), which markedly compressed the spinal cord. (C) Local recurrence was detected at C5- 6 and tumor excision (2nd 
operation) was then performed after 1 year from the initial diagnosis. An arrow indicates the tumor. (D) The residual tumor (arrow). (E) Sagittal, MRI 
T2 fat suppression image. The tumors markedly enlarged and severe pain occurred in his left hand. The tumor of C2- 4 was resected, while the tumor 
of C5- 6 was unresectable. Zaltoprofen (240 mg/day) was then administrated for the pain. (F) Before the final operation for severe cervical kyphosis, 
MRI T2 fat suppression image showed the localized tumor of C5- C6 remained.
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therapeutic target to reduce local spread and invasion in 
chondrosarcomas. Lai et al. reported that alendronate, a 
second- generation bisphosphonate, inhibited MMP2 pro-
duction and the invasion of a chondrosarcoma cell line 
[15]. Recent studies have also demonstrated that PPARγ 
activation could inhibit cell migration and invasion through 
the downregulation of MMP2 in cancer cells [16, 17]. In 
this study, we first discovered the downregulation of MMP2 
activity in a PPARγ- dependent fashion by zaltoprofen.
We experienced a case of chondrosarcoma with unin-
tentional zaltoprofen treatment. (Fig. 5). It is known that 
grade 2 chondrosarcoma progresses destructively and metas-
tasizes. Local recurrence and metastasis rates have been 
reported to be 27% and 50%, respectively, in grade 2 
chondrosarcoma, and 70% of chondrosarcoma cases with 
local recurrence have developed metastasis [32]. Interestingly, 
for approximately 2 years during administration of zalto-
profen, the tumor remained localized without distant metas-
tasis even though the tumor was grade 2 chondrosarcoma. 
Histopathological findings showed upregulation of PPARγ 
and downregulation of MMP2 after the administration of 
zaltoprofen in the patient (Fig. 6). We believe that a long- 
term administration of zaltoprofen could reduce the local 
spreading and metastatic abilities of the tumor cells.
In conclusion, this study showed that zaltoprofen acti-
vated PPARγ and subsequently decreased MMP2 activity 
in human chondrosarcoma cells, thereby contributing 
to anti- tumor effects against cell viability, proliferation, 
migration, and invasion. A beneficial effect of zaltoprofen 
was also demonstrated in a patient with grade 2 chon-
drosarcoma. Therefore, these findings suggest that zal-
toprofen could be a novel promising remedy against 
chondrosarcomas via PPARγ activation and MMP2 inhi-
bition. Future studies using orthotopic xenograft mouse 
models will be required to show the in vivo effect of 
zaltoprofen on chondrosarcomas, based on previous 
reports of osteosarcoma [33, 34], rhabdomyosarcoma 
[35], and undifferentiated pleomorphic sarcoma [36–38] 
with various anti- cancer drugs. In addition, large pro-
spective cohort studies will be required to draw a final 
conclusion about the efficacy of zaltoprofen and to evalu-
ate the effect of clinical applications in patients with 
chondrosarcoma.
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Figure 6. Histopathological findings of the tumors at the second operation (preadministration of zaltoprofen, Pre) and the final operation 
(postadministration of zaltoprofen, Post). Scale bar = 25 μm. (A) HE staining. (B, C) Immunofluorescent stainings for PPARγ (B) and MMP2 (C). DAPI, 
a nuclear staining.
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